Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT001 plus whole-brain radiotherapy for brain metastases from solid tumors
ChiCTR2000037739Phase 2Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of dimethylaminomicheliolide in brain metastases (3 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Adverse events and One-year intracranial progression-free survival rate. Started Apr 2020; status: completed.
02
Drugs
dimethylaminomicheliolide
03
Conditions
brain metastases
Beyond the preview
Go deeper on ChiCTR2000037739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037739.